Answers are grounded in this paper and cite their sources.
Objectives Sepsis mortality remains persistently high. This work sought to assess the diagnostic and prognostic utility of miR-7110-5p in sepsis and to explore its mechanism of regulating macrophage inflammatory responses through targeting TRIM3. Methods This study included 108 healthy controls and 114 septic patients. Serum miR-7110-5p was measured for clinical relevance, diagnostic performance, and 28-day prognostic value. In vitro, RAW264.7 macrophages were Lipopolysaccharide (LPS)-stimulated and transfected with miR-7110-5p inhibitor, alone or with TRIM3 siRNA for rescue. qRT-PCR measured miR-7110-5p, TRIM3, and M1/M2 markers. Inflammatory cytokines and cell viability were assessed by ELISA and CCK-8, respectively. The miR-7110-5p-TRIM3 interaction was verified by dual-luciferase assay. Results Serum miR-7110-5p was elevated in septic patients (AUC = 0.909) and independently predicted 28-day mortality. In LPS-stimulated RAW264.7 macrophages, miR-7110-5p was upregulated, with increased M1 markers (CD80, iNOS) and decreased M2 markers (CD206, Arg-1), along with enhanced TNF-α/IL-6/IL-1β secretion and reduced cell viability. TRIM3 was downregulated in septic patients, and dual-luciferase assay confirmed that miR-7110-5p directly binds to TRIM3. miR-7110-5p inhibition reversed these effects, while TRIM3 knockdown partially offset this protection. Conclusions miR-7110-5p is markedly upregulated in sepsis and exhibits diagnostic and prognostic potential. Mechanistically, it exacerbates LPS-induced inflammatory injury through targeted suppression of TRIM3. The miR-7110-5p/TRIM3 axis may thus represent a candidate target for sepsis intervention.
No takes yet. Share an insight, caveat, or question.
Gui et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: